TABLE 1

Analysis sets

Analysis setaNo. (%) of patients
CadazolidVancomycin (125 mg QID)Total
250 mg BID500 mg BID1,000 mg BID
All randomized20 (100)22 (100)20 (100)22 (100)84 (100)
mITT17 (85.0)20 (90.9)19 (95.0)22 (100)78 (92.9)
PP16 (80.0)19 (86.4)17 (85.0)19 (86.4)71 (84.5)
SS20 (100)22 (100)20 (100)22 (100)84 (100)
  • a The mITT set included all randomized patients who received ≥1 dose of the study drug and had a confirmed diagnosis of CDI (positive toxigenic culture by a central laboratory), the PP (per-protocol) set included all patients from the mITT set without major protocol deviations or other conditions that might affect the evaluation of the primary endpoint, and the SS (safety set) included all randomized patients who received ≥1 dose of the study drug.